VAD044, an oral, once-daily allosteric AKT inhibitor, represents a novel therapeutic approach specifically designed for the treatment of hereditary hemorrhagic telangiectasia (HHT). This evidence concerns the gene AKT1 and hereditary hemorrhagic telangiectasia.